BNP Paribas Financial Markets Portfolio holdings
BNP Paribas Financial Markets, a core component of BNP Paribas’s Corporate & Institutional Banking (CIB) division, is a global leader in trading and market-making, headquartered in Paris with major hubs in London, New York, Hong Kong, and Singapore. Specializing in derivatives across all asset classes—equities, fixed income, commodities, and foreign exchange—it provides innovative investment, hedging, and financing solutions to corporate clients, institutional investors, and financial institutions worldwide. Known for its advanced technological infrastructure and quantitative expertise, the division excels in structured financing and electronic trading, supported by a robust balance sheet and a diversified business model that proved resilient during the 2008 financial crisis. With a presence in over 50 countries and a client base exceeding 13,000, BNP Paribas Financial Markets drives market liquidity and offers cutting-edge research and execution services, reinforcing its position as a top-tier player in global capital markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$2.42B |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.87B |
| 3 |
iShares Russell 2000 ETF
IWM
|
+$704M |
| 4 |
State Street Industrial Select Sector SPDR ETF
XLI
|
+$517M |
| 5 |
Nike
NKE
|
+$489M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
XLNX
Xilinx Inc
XLNX
|
+$301M |
| 2 |
State Street Health Care Select Sector SPDR ETF
XLV
|
+$283M |
| 3 |
State Street SPDR S&P Retail ETF
XRT
|
+$156M |
| 4 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$72M |
| 5 |
NVIDIA
NVDA
|
+$68.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 12.15% |
| 2 | Consumer Discretionary | 6.92% |
| 3 | Financials | 5.66% |
| 4 | Healthcare | 5.15% |
| 5 | Industrials | 3.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2901
Simulations Plus
SLP
$371M
| $229K | ﹤0.01% |
4,490
-16,389
| -78% | -$704K |
|
2902
Freshpet
FRPT
$3.48B
| $229K | ﹤0.01% |
2,229
-16
| -0.7% | -$1.51K |
|
2903
iShares 5-10 Year Investment Grade Corporate Bond ETF
IGIB
$18.6B
| $227K | ﹤0.01% |
4,146
+1,871
| +82% | +$106K |
|
|
EVBG
2904
PUT
DELISTED
Everbridge, Inc. Common Stock
EVBG
| $227K | ﹤0.01% |
52
+2
| +4% | +$94 |
|
2905
Inogen
INGN
$154M
| $226K | ﹤0.01% |
6,977
-3,645
| -34% | -$115K |
|
2906
American Superconductor
AMSC
$1.56B
| $226K | ﹤0.01% |
29,672
+17,916
| +152% | +$153K |
|
2907
Equity Bancshares
EQBK
$1.06B
| $225K | ﹤0.01% |
6,950
-13,414
| -66% | -$436K |
|
|
PRO
2908
DELISTED
PROS Holdings
PRO
| $224K | ﹤0.01% |
6,712
-5,719
| -46% | -$176K |
|
2909
Ameresco
AMRC
$1.47B
| $223K | ﹤0.01% |
2,806
-3,726
| -57% | -$235K |
|
2910
John B. Sanfilippo & Son
JBSS
$989M
| $223K | ﹤0.01% |
2,671
-3,443
| -56% | -$285K |
|
2911
Lexicon Pharmaceuticals
LXRX
$1.04B
| $223K | ﹤0.01% |
106,564
+3,220
| +3% | +$8.93K |
|
|
CPRX
2912
DELISTED
Catalyst Pharmaceutical
CPRX
| $223K | ﹤0.01% |
26,858
-27,143
| -50% | -$192K |
|
2913
Riot Platforms
RIOT
$7.21B
| $220K | ﹤0.01% |
10,382
-9,649
| -48% | -$174K |
|
|
DBD
2914
DELISTED
Diebold Nixdorf Incorporated
DBD
| $219K | ﹤0.01% |
32,591
-8,115
| -20% | -$69.4K |
|
2915
V2X
VVX
$2.55B
| $219K | ﹤0.01% |
6,115
-2,490
| -29% | -$106K |
|
|
DCPH
2916
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $218K | ﹤0.01% |
23,557
+3,417
| +17% | +$29.1K |
|
2917
Amerant Bancorp
AMTB
$1.15B
| $218K | ﹤0.01% |
6,910
-4,320
| -38% | -$143K |
|
2918
Sutro Biopharma
STRO
$353M
| $218K | ﹤0.01% |
2,648
+947
| +56% | +$90.1K |
|
|
BFS
2919
Saul Centers
BFS
$850M
| $218K | ﹤0.01% |
4,129
-1,721
| -29% | -$84.3K |
|
|
TRHC
2920
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
| $217K | ﹤0.01% |
37,692
+11,072
| +42% | +$99.4K |
|
2921
Banco Bilbao Vizcaya Argentaria
BBVA
$157B
| $217K | ﹤0.01% |
38,105
-6,915
| -15% | -$42.3K |
|
2922
Marcus Corp
MCS
$914M
| $216K | ﹤0.01% |
12,214
-80,832
| -87% | -$1.42M |
|
2923
Gossamer Bio
GOSS
$83.3M
| $216K | ﹤0.01% |
24,833
-6,130
| -20% | -$59.1K |
|
2924
Noodles & Co
NDLS
$98M
| $215K | ﹤0.01% |
4,508
-1,882
| -29% | -$116K |
|
2925
National CineMedia
NCMI
$252M
| $215K | ﹤0.01% |
8,464
+2,237
| +36% | +$62.3K |
|
Similar funds
BNP Paribas Financial Markets's Q1 2022 Portfolio in Review
As of Q1 2022, BNP Paribas Financial Markets held 4,480 positions worth $74.4B, up 5.9% from $70.2B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
BNP Paribas Financial Markets deployed $8.44B of net new capital in Q1 2022, opening 238 new positions and adding to 1,135 existing holdings. Its largest new stake was Invesco Emerging Markets Sovereign Debt ETF: 1,028,214 shares worth $23.2M.
By sector, the portfolio is most concentrated in Technology at 12% of assets, down from 13% a quarter earlier, followed by Consumer Discretionary and Financials.
On the sell side, the largest reduction was State Street Health Care Select Sector SPDR ETF, an estimated $283M trimmed.
- BNP Paribas Financial Markets's largest Q1 2022 buy was Invesco Emerging Markets Sovereign Debt ETF: 1,028,214 shares worth $23.2M.
- BNP Paribas Financial Markets added most to Invesco QQQ Trust in Q1 2022, an estimated $2.42B increase.
- BNP Paribas Financial Markets's biggest Q1 2022 reduction was State Street Health Care Select Sector SPDR ETF, cutting an estimated $283M.
- BNP Paribas Financial Markets fully exited Xilinx Inc in Q1 2022, selling an estimated $301M.
- BNP Paribas Financial Markets's ten largest holdings make up 19% of its $74.4B portfolio in Q1 2022.
- BNP Paribas Financial Markets opened 238 new positions and closed 335 in Q1 2022.
- BNP Paribas Financial Markets's portfolio value rose 5.9% quarter-over-quarter to $74.4B.
Based on BNP Paribas Financial Markets's 13F filing for Q1 2022, filed 17 May 2022.